Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Autoinjectors Market worth $300.46 billion by 2031 | MarketsandMarkets™

prnewswire.com
BDX Mentioned as a top company in the growing autoinjectors market, indicating potential relevance and participation in market expansion. ABBV Listed as a key player in the finished formulation autoinjectors market, suggesting its involvement in a growing sector. LLY Identified as a key player in the finished formulation autoinjectors market, indicating its participation in a growing area.

Autoinjectors Market worth $300.46 billion by 2031 | MarketsandMarkets™ DELRAY BEACH, Fla., March 31, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Autoinjectors Market is projected to grow from about USD 127.30 billion in 2026 to USD 300.46 billion by 2031, at a CAGR of 18.7%.

Browse through 550 market data tables and 65 figures spread across 500 pages, as well as the in-depth TOC on the "Autoinjectors Market - Global Forecast to 2031"

Autoinjectors Market Size & Forecast:

Autoinjectors Market Trends & Insights:

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724

The autoinjectors market is experiencing substantial growth due to several key factors. The increasing prevalence of chronic and autoimmune diseases, such as diabetes, cancer, cardiovascular conditions, multiple sclerosis, and rheumatoid arthritis, has heightened the demand for long-term injectable treatments. A growing global population further boosts demand, as an increase in population correlates with a rise in chronic diseases that require long-term injectable therapies, thus fueling the autoinjector market. Additionally, the expansion of healthcare infrastructure in developing regions and greater access to hospitals and treatments have opened new markets for autoinjectors. Technological progress also plays a critical role, with safer, more efficient, and user-friendly autoinjector devices being more widely adopted by healthcare providers and patients. Overall, these trends are driving consistent growth in the autoinjector industry worldwide.

By usage, the disposable autoinjectors segment is expected to register the highest CAGR during the forecast period.

the market is divided into disposable autoinjectors and reusable autoinjectors. In 2025, disposable autoinjectors was the fastest-growing segment, driven by their ease of use, increasing demand for self-administration, and lower risk of cross-contamination or infection, making them highly favored in modern healthcare environments. Innovations in reusable autoinjectors, such as digital interfaces, ergonomic designs, and greater awareness of sustainability, are boosting the adoption of reusable autoinjectors.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=142006761

By actuation mechanism, the mechanical (spring-based) autoinjectors segment held the largest share of the market in 2025.

the market is segmented into mechanical (spring-based) autoinjectors and electronic autoinjectors. Mechanical autoinjectors account for the largest share of the autoinjectors market, driven by their simpler design, reliability, and cost-effectiveness. The growth is further supported by patients preferring the unique click sound that provides physical confirmation that the injection has begun or ended. However, advancements in electronic autoinjectors, such as integration of digital connectivity, real-time feedback, mobile tracking, and adherence monitoring, are supporting the widespread adoption of electronic autoinjectors.

By drug type, biologics are projected to register the highest growth rate in the autoinjectors market.

the market is segmented into biologics, biosimilars, and small molecules. Biologics is the dominant segment of the autoinjectors market, driven by increasing use in treating chronic diseases such as diabetes, arthritis, and oncology. The growing pipeline of monoclonal antibodies and other injectable biologics has also further supported the growth of the biologics segment in the autoinjectors market. Since high-viscosity biologics require motorized delivery, autoinjectors remain a preferred choice, which further fuels the demand for autoinjectors.

The market in North America is expected to hold the largest share of the autoinjectors market throughout the forecast period.

North America leads the global autoinjectors market mainly because of its high healthcare spending, strong reimbursement policies, and the increasing shift toward home-based treatment. The region also benefits from the concentration of major pharmaceutical and medical device hubs. Meanwhile, the Asia Pacific region is expected to see the highest CAGR in the autoinjectors market during the forecast period. This growth is fueled by improvements in healthcare infrastructure, substantial investments in local manufacturing, and a growing population. Consequently, demand for autoinjectors is climbing in this area.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=173991724

Top Companies in Autoinjectors Market:

The Top Companies in Autoinjectors Market include Becton, Dickinson and Company (US), SHL Medical (Switzerland), and Ypsomed (Switzerland). Key players in the finished formulation autoinjectors market include Novo Nordisk (Denmark), AbbVie Inc. (US), and Eli Lilly and Company (US).

Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting

Related Reports:

Insulin Delivery Devices Market - Global Forecast to 2030

Pen Needles Market - Global Forecast to 2030

Wearable Injectors Market - Global Forecast to 2030

Injection Pen Market - Global Forecast to 2030

Injectable Drug Delivery Market - Global Forecast to 2030

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:

Mr. Rohan Salgarkar

MarketsandMarkets™ INC.

1615 South Congress Ave.

Suite 103, Delray Beach, FL 33445

USA: +1-888-600-6441

Email: [email protected]

Visit Our Website: https://www.marketsandmarkets.com/

Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets